Rapid communication · 28 Apr 2025
Research articlePublished 7 Jan 2019
A phase-2 study of high-dose pineal antitumor hormone Melatonin as an adjuvant therapy in triple negative breast cancer.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
It is known that triple negative breast cancer (TNBC) is the most prognostically negative mammary tumor, because of its lack of sensitivity to the main growth factors for breast cancer, including estrogens and EGF. However, at least three other hormones would have to be considered, consisting of prolactin (PRL), oxytocin (OT), and the pineal hormone melatonin (MLT). PRL would stimulate TNBC growth, whereas MLT and OT would play an inhibitory action in several tumor histotypes, including TNBC, even though at present only clinical studies with MLT have been performed, by demonstrating that it?s in human anticancer activity is a dose-dependent phenomenon. On these bases, a study was planned to evaluate the effects of high-dose MLT chronic administration as an adjuvant therapy on the percent of 3-year progression-free period (PSF) in TNBC after adjuvant chemotherapy. The study included 14 consecutive TNBC patients, who were treated with MLT at 40 mg/day orally in the evening every day without interruption, by comparing the results to those observed in a control group of 16 TNBC patients with comparable clinical characteristics. The 3-year PFS percentage achieved in MLT group was significantly higher than that found in the control group, either in patients with or without node involvement. No MLT-related biological toxicity occurred. On the contrary, most patients referred a mood improvement. These preliminary results justify further randomized study with or without high-dose MLT in TNBC patients, in an attempt to prolong their survival.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cancer Immunology & Therapy.
Perspective · 28 Apr 2025
VT-Cell Exhaustion vs. Activation: Implications for Immunotherapy
Commentary · 28 Apr 2025
The Role of Costimulatory Molecules in T-Cell Activation
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cancer Immunology & Therapy
- SubjectOncology & Cancer
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Paolo Lissoni”
- BylineArticles whose byline prints “Franco Rovelli”
- BylineArticles whose byline prints “Giusy Messina”
- BylineArticles whose byline prints “Vezika Cenaj”
- BylineArticles whose byline prints “Giorgio Porro”
- BylineArticles whose byline prints “Giuseppe Di Fede”
